Earth Science Tech Initiates its Cannabis Cannabin

Hollywood, Feb. 23, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the Company"), an innovative biotech company focused on hemp cannabinoid research and development, has begun composition work on its two (2) new Cannabis Cannabinoid-Based pharmaceutical drugs and has initiated patent studies on its three (3) new nutraceutical products. This is the first project Earth Science Tech and its wholly owned subsidiary, Cannabis Therapeutics, are working with Smart Medicines GMP on as a result of the Company’s recently finalized joint venture .

Earth Science Tech and Cannabis Therapeutics two (2) new Cannabis Cannabinoid-Based pharmaceutical drug formulations (compositions) are expected to be completed by summer 2017, with non-prescription nutraceuticals being available for sale before the end of the year and the pharmaceutical-grade products being launched in the first or second quarter of 2018. Earth Science Tech and Cannabis Therapeutics initial patent-pending Cannabinoid-Based nutraceutical product/products being developed seek to offer a broad spectrum of health protection, including immune system strengthening properties and strong antioxidant properties among a variety of other heath & overall wellness benefits. Another nutraceutical Cannabinoid-Based product in the pipeline seeks to improve and protect brain and liver function, which can improve the quality of life for patients, especially those experiencing harsh side effects from traditional medicines. The final nutraceutical to be developed is a prophylactic that aims to prevent some of the more common causes of cancer to help reduce occurrence rates. After the Company’s initial formulation work on the immune system-focused nutraceutical is finished, work will begin on a prescription depression, anxiety, and PTSD treatment. Once the mental illness drug formulation is finished, focus will be shifted toward developing a pharmaceutical-grade cancer treatment, with an emphasis on breast and brain cancers. Both of these pharmaceutical products will include CBD hemp oil and pure natural molecules, combined with generic drugs. Earth Science Tech and Cannabis Therapeutics look to offer patients the unique health benefits of CBD treatments with the proven backing of reliable, tried and true cancer and mental illness fighting drugs. “We are very excited to be making such big strides in our relationship with Smart Medicines GMP after such a short time,” said CEO, Dr. Michel Aubé, “We are building products that we feel could find mass-market acceptance, as they will leverage the well-documented strengths of several existing drugs.” Earth Science Tech and its wholly owned subsidiary, Cannabis Therapeutics, have been working zealously with Smart Medicines GMP, to invent & launch these Two (2) New Cannabinoid-based Pharmaceutical drugs and Three (3) New Advanced Cannabinoid-based Nutraceutical products using Earth Science Tech’s existing Cannabis CBD Patent, IP, Invention, Technology and future Technology . ETST’s International Application (PCT) for its Provisional Patent named “Cannabidiol Compositions Including Mixtures and Uses Thereof” was filed on October 8th, 2015 in regards to its Cannabis Hemp CBD (Cannabidiol) Oil. This application claims the benefit of ETST U.S. Provisional Application N. 62/061,577, filed October 8, 2014 and ETST U.S. Provisional Application No. 62/102,538, filed January 12, 2015. As previously announced, ETST wholly owned subsidiary, Cannabis Therapeutics, primary goal is to discover solutions for conditions for which there is presently no effective treatment as well as other medical disorders with the application of known and novel cannabis cannabinoid-based products. Some of the R&D that Cannabis Therapeutics will target will be treatments for the conditions and disorders of: Pain, Chronic Pain , PTSD , Breast Cancer , Brain Cancer , Anxiety , Depression , Glaucoma , Crohn’s disease , Fatty Liver Diseases , Diabetes , Parkinson' s Disease , Alzheimer's Disease , Attention Deficit Hyperactivity Disorder (ADHD) , and Drug Addictions  among other things. 

ETST has chosen to target diseases for which, the benefits of Cannabinoids and/or CBD (Cannabidiol) have already been demonstrated by different groups of researchers around the world. However, it is through ETST’s in vitro study with the University of Central Oklahoma and DV Biologics that results confirm the positive effectiveness of Earth Science Tech’s CBD (Canabidiol) on breast cancer , immune cell function , and human brain cells  by acting as a neuroprotectant as shown in its International Application (PCT) for its Provisional Patent. Thus, as a result by mixing natural molecules and generic pharmaceutical drugs with Cannabinoids and/or CBD (Cannabidiol) we intend to increase the effectiveness of Cannabinoids and/or CBD (Cannabidiol) and improve the treatment of different diseases. Per Earth Science Tech’s recent joint venture release with Smart Medicines GMP, Smart Medicines is equipped with a state-of-the-art laboratory and research facilities with high tech equipment and botanical extraction units. Smart Medicines will focus heavily on the research and development tasks associated with new product development. This partnership will help position Cannabis Therapeutics to be a global leader in the cannabis industry and in cannabinoid research and development. Cannabis Therapeutics’ imminent new developments and efforts have the potential to expedite our numerous upcoming cannabis cannabinoid-based therapeutic products to help aid people with certain conditions and disorders worldwide, in the later part of 2017. ETST is focused on cannabinoid-based therapeutic drugs, functional foods and nutraceuticals (retail consumer markets worldwide). Smart Medicines is run by Dr. Domenico Fuoco, who recently joined the Advisory Board of Cannabis Therapeutics, Inc. (an Earth Science Tech subsidiary). Dr. Fuoco has over 16 years of extensive experience in developing innovative solutions for the pharmaceutical and nutraceutical industries in addition to his current status as a professional formulator. Dr. Fuoco and company’s expertise are expected to be of great benefit to Earth Science tech in its new product creation. View Dr. Fuoco’s full biography below. Smart Medicines and Earth Science Tech have close ties with CQIB ( http://www.cqib.org/home.html ), a biotech and life sciences incubator. They will work closely with CQIB to improve upon and further develop their patents while developing a stronger product portfolio. This relationship will further provide both companies access to top-of-the-line research and development equipment and laboratories to provide the most accurate of results. About Earth Science Tech, Inc. (ETST): Earth Science Tech ( www.earthsciencetech.com ) is a publicly traded (ETST) unique Science based Biotechnology company focused on cutting edge Nutraceuticals, Bioceuticals, Phytoceuticals and Cosmeceuticals for the Health, Wellness and Alternative Medicine Markets to help improve the quality of life for Consumers Worldwide. ETST is also dedicated to providing Natural Alternatives to prescription medications through the use of its cutting edge Nutritional and Dietary Supplements. This may include products such as its High-Grade Hemp CBD (Cannabidiol) Oil, Vitamins, Minerals, Herbs, Botanicals, Personal Care Products, Homeopathies, Functional Foods and other products. These products may be in various formulations and delivery systems including (but not limited to) capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders, and whole herbs. ETST is focused on researching and developing innovative Hemp extracts and to make them accessible Worldwide. ETST plans to be the premier supplier of the highest quality and purity of High Grade Hemp CBD (Cannabidiol) Oil. ETST's primary goal is to advance different High Quality Hemp extracts with a broad profile of Cannabinoids and additional natural molecules found in Industrial Hemp and to identify their distinct properties. The company is dedicated in offering its consumers the finest and purest quality All Natural-Organic Hemp CBD Oil while never compromising on quality. ETST High Grade Hemp CBD (Cannabidiol) Oil is classified as "food based" and therefore perfectly permissible in all 50 states and more than 40 countries. Cannabinoids (Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD possesses no psychoactive qualities and presents a continuing stream of overwhelming evidence of significant Wellness benefits. With no psychoactive ingredient, Hemp CBD Oil is a ready-for-market Hemp-based Nutraceutical. The United States Food and Drug Administration (FDA) currently considers non-THC hemp based cannabinoids, including CBD, to be "food based" and therefore saleable. These new non-psychoactive CBD-rich hemp oil products that ETST has geared up to market and distribute are beyond reproach. CBD (cannabidiol), a naturally occurring constituent of the Industrial Hemp plant, promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 "Cannabinoids as antioxidants and neuroprotectants." ETST does not grow, sell or distribute any substances that violate United States Law or the controlled substance act. ETST does sell and distribute cannabis industrial hemp based products. About Cannabis Therapeutics:  Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide. The company is currently working on finishing the launch of its new corporate website at www.Cannabisthera.com   FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products. SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Dave Demarest (305)-546-7640 Earth Science Tech, Inc. Nickolas S. Tabraue, P/D/COO (305)-615-2118